Cancer Mutation Detection via Restriction Enzyme Digestion and PCR
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting cancer-related mutations in DNA samples, such as those in clinical settings or circulating tumor DNA, are often laborious, expensive, insufficiently sensitive, or specific, and require complex processing, making them unsuitable for routine clinical testing.
Innovation Solution
The method involves selective digestion of wild-type DNA using restriction enzymes, allowing mutated DNA to remain intact for subsequent PCR amplification and analysis, with the calculation of signal intensity ratios between amplification products of a restriction locus and a control locus to accurately detect cancer-related mutations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If next-generation sequencing (NGS) is used for detecting cancer mutations, then detection sensitivity and comprehensiveness are improved, but cost and operational complexity increase significantly
Solution Approach 1:
The patent extracts and focuses on detecting only specific cancer-related mutations at predetermined locations rather than performing comprehensive sequencing of all genetic material. This targeted approach uses PCR primers designed to amplify only regions containing known cancer mutations, eliminating the need for complex NGS infrastructure while maintaining clinical relevance.
Solution Approach 2:
The patent employs disposable PCR strips with pre-loaded reagents including primers, probes, and master mix. These single-use strips eliminate the need for complex instrument calibration and cleaning procedures required by NGS systems, reducing operational complexity while maintaining detection sensitivity through optimized reagent formulations.
2Measurement precision
If comprehensive PCR amplification of all DNA regions is performed, then detection coverage is improved, but processing time and resource consumption increase
Solution Approach 1:
The patent segments the DNA analysis task by designing separate PCR reactions for different cancer-related genes and mutation types. Each PCR strip is configured to detect specific mutations (e.g., EGFR, KRAS, BRAF) independently, allowing parallel processing of multiple samples and reducing total processing time while maintaining comprehensive cancer panel coverage.
Solution Approach 2:
The patent performs preliminary selection of target regions by designing PCR primers that specifically bind to known cancer mutation sites before amplification. This pre-targeting approach eliminates the need for time-consuming whole-genome amplification steps, directly jumping to the detection of clinically relevant mutations.
3Adaptability or versatility
If multiple PCR reactions are performed to detect different mutations, then detection versatility is improved, but procedure complexity and cost increase
Solution Approach 1:
The patent merges multiple detection capabilities into a single integrated PCR strip by incorporating multiple primer pairs and fluorescent probes that detect different cancer mutations simultaneously. Each strip can detect multiple genes (EGFR, KRAS, BRAF, NRAS) and various mutation types (point mutations, insertions, deletions) in one reaction, eliminating the need for separate assays.
Solution Approach 2:
The patent creates universal PCR strips that can detect a broad spectrum of cancer mutations across multiple genes using a standardized protocol. The same basic assay platform and analysis workflow can be applied to different cancer types and mutation profiles, providing versatility without requiring separate optimized procedures for each detection scenario.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides a simple, cost-effective, and highly sensitive method for detecting cancer-related mutations, capable of identifying mutations in tumor tissues or plasma samples with high specificity, facilitating accurate patient management and treatment decisions.
Implementation Method 1
subjecting the DNA sample to digestion with a restriction endonuclease to obtain restriction endonuclease-treated DNA
Implementation Method 2
co-amplifying from the restriction endonuclease-treated DNA a restriction locus comprising a cancer mutation site and a control locus, thereby generating an amplification product for each locus
Data Source
AI summary
Methods and kits for detection of cancer-related mutations in a DNA sample using enzymatic restriction and real-time PCR. A DNA sample is subjected to digestion with a restriction endonuclease to obtain restriction endonuclease-treated DNA, followed by co-amplification of a restriction locus comprising a cancer mutation site and a control locus. A ratio of signal intensities of the amplification products of the restriction locus and the control locus is used to detect the cancer-related mutation.